Canaccord lowered the firm’s price target on Ultragenyx (RARE) to $79 from $128 and keeps a Buy rating on the shares. The firm said its 4Q25 report was fine on the commercial side and our focus was on the details around restructuring post disappointing OI news. But they do like the setup for Ph3 data from GTX-102 for Angelman syndrome in 2H26 which they expect will be positive and key inflection point for shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target lowered to $37 from $39 at Evercore ISI
- Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright
- Ultragenyx price target lowered to $45 from $50 at Citi
- Ultragenyx Earnings Call Balances Growth With Risk
- Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures